On June 2, 2023 Sanofi reported that it will present new data at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from June 2-6, including an oral presentation where results will be shared for the first time of a first-in-human study of an investigational trifunctional anti-CD123 natural killer (NK) cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia (Press release, Sanofi, JUN 2, 2023, View Source [SID1234632396]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Peter Adamson
Global Development Head, Oncology
"The presentation of data at ASCO (Free ASCO Whitepaper) from our initial clinical trial of SAR443579, a novel NK cell engager, supports the potential of this investigational approach for patients with hematologic malignancies. At Sanofi, we are continuing to build our early oncology pipeline, which leverages leading-edge R&D platforms, to drive a range of investigational approaches for patients with difficult-to-treat cancers."
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR443579 for the treatment of hematological malignancies. Fast Track Designation is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical need. The FDA created this process to help deliver important new drugs to patients earlier, and it covers a broad range of serious illnesses.
Olivier Nataf
Global Head, Oncology
"Having recently joined Sanofi as Global Head, Oncology, I am looking forward to coming together with the global oncology community at ASCO (Free ASCO Whitepaper) to discuss the future of cancer treatment and latest oncology research. This year, we are focused on highlighting our pipeline and exploring new opportunities that allow us to continue helping those living with cancer. Cancer is complex and we understand that innovation does not happen in isolation, so exploring strategic partnerships and collaborations that align science and technology with evolving medical needs is essential to our journey."
Sanofi’s oncology pipeline has doubled since 2019, and we are exploring the advancement of potentially transformative therapies and focusing research on areas of high unmet needs for those living with various types of cancer.
Other Sanofi data to be presented at ASCO (Free ASCO Whitepaper) include studies in several priority areas of focus, such as relapsed multiple myeloma, advanced solid tumors and non-small cell lung cancer.
Early data for SAR443579, an investigational trifunctional anti-CD123 NK cell engager*
Abstract #7005: A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia
Updated results of the Phase 3 IKEMA study of Sarclisa (isatuximab) in relapsed multiple myeloma
Abstract #8029: Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: updated results from the Phase 3 IKEMA study
Early safety results of investigational tusamitamab ravtansine in advanced solid tumors*
Abstract #e15003: Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: pooled safety analysis of corneal adverse events
Analysis of extended adjuvant endocrine therapy in HR+/HER2- breast cancer
Abstract #e12509: Side effects and impacts of extended adjuvant endocrine therapy: A qualitative study among women with HR+/HER2- breast cancer
Click here to view these abstracts located in the ASCO (Free ASCO Whitepaper) Meeting Library.
*These assets are currently under investigation and their safety and efficacy has not been fully evaluated by any health authority.